gebhart/patrepeval huggingface dataset:
Representing Indigenous Bodies in Epeli Hau'ofa and Syaman Rapongan (2010)

This paper explores the representation of indigenous bodies within the context of the trans-indigenous Pacific. Drawing on the life narratives of Epeli Hau'ofa and Syaman Rapongan, two authors native to the Pacific region, I argue that Pacific indigenous body politics are connected to an ”oceanic” body and constitute a counter-conversion from land to sea. In We Are the Ocean (Hau'ofa, 2008) as well as Cold Sea, Deep Passion (Rapongan, 1997) and Black Wings (Rapongan, 1999), the two authors set out to liberate the indigenous body from the limitations of nationalistic discourse and social constraint; the respective resolutions of their life stories point us toward solutions to global problems of discrimination and ethnic or racial exclusion. In these works, the indigenous body is a cultural cipher, an index of (post)colonial history, as well as a figure upon which the cultural identities and life paths of Pacific indigenous peoples are inscribed.
Remote Ischemic Conditioning in Patients With Myocardial Infarction Treated With Primary Angioplasty (2010)

although no significant overall effect was observed, rIC seemed to result in modest improvement in LV function in high-risk patients prone to develop large myocardial infarcts. These results need to be confirmed in larger trials.
Proton Radiation and TNF-α/Bax Gene Therapy for Orthotopic C6 Brain Tumor in Wistar Rats (2004)

High-grade tumors of the brain remain virtually incurable with current therapeutic regimens, new approaches to augment existing therapies need to be explored. The major goal of this pilot study was to evaluate the feasibility of gene therapy using plasmid DNA encoding tumor necrosis factor-alpha and bax together with proton radiation in an immunocompetent animal model with orthotopic brain tumor. C6 glioma cells were stereotactically implanted into the left hemibrain of Wistar rats (day 0). On day 5, the appropriate groups received intratumoral pGL1-TNF-a and pGL1-Bax (10 microg each), parental plasmid pWS4 (20 microg), or PBS. Hemibrain proton irradiation (10 Gy, 90 MeV, single fraction) was delivered 18-20 hr later. Rats were euthanized when signs of illness appeared. In addition, a subset of animals from each group was euthanized on day 9 for immune and other assays. By day 9, 25%, 20%, and 10% of rats treated with PBS, pWS4, or pGL1-TNF-alpha/pGL1-Bax, respectively, had been euthanized due to weight loss or other signs of illness, whereas all rats treated with pGL1-TNF-alpha/pGL1-Bax + radiation or radiation alone were healthy (P<0.05). At this same time, the pGL1-TNF-alpha/pGL1-Bax + radiation group had significantly elevated lymphocyte percentages (P<0.005 or less) and a relatively high level of lymphocytic infiltrate within tumors. Although the rats treated with pGL1-TNF-alpha/pGL1-Bax had the highest levels of activated T helper (CD4+/CD71+) and T cytotoxic (CD8+/CD71+) cells, the values were not significantly different compared to the pWS4-injected control group. Splenocytes in all tumor cell-injected groups had higher mean values for DNA and protein synthesis compared to the non-tumor cell injected control group, whereas oxygen radical production by phagocytes was consistently higher in groups injected with plasmid or treated with radiation. Body, hemibrain, and spleen masses, white blood cell, red blood cell and platelet counts, hemoglobin, hematocrit, and transforming growth factor-beta1 levels in plasma were similar among groups. The results demonstrate that treatment with pGL1-TNF-alpha/pGL1-Bax combined with proton hemibrain irradiation is safe under the conditions used. Overall, these data support further investigation of this unique combination therapy.
Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study. (2007)

Abstract Background: A previous CALGB trial (JCO2002;20:2429) showed a positive OS trend with AZA vs best supportive care (BSC) in MDS. The objective of this Phase III, international, multicenter, randomized, prospective trial was to demonstrate the superiority of AZA + BSC for prolonging OS vs CCR + BSC. Design: Higher-risk MDS patients (pts), FAB-defined as RAEB, RAEB-T, or CMML (10–29% marrow blasts) with an IPSS of Int-2 or High by central pathology/cytogenetic review, were enrolled. Before randomization, investigators preselected pts to 1 of 3 CCR: BSC only (transfusions, antibiotics, and G-CSF for neutropenic infection); low-dose ara-C (LDAC, 20 mg/m2/d x 14d, q 28d); or standard chemotherapy (Std CT: conventional induction/consolidation). Pts were stratified by FAB/IPSS and randomized to AZA (75 mg/m2/d x 7d, q 28d) or CCR. This trial did not allow erythropoietin. All analyses used the ITT population. Results: In all, 358 pts (70% male), were randomized at 79 sites to AZA (N=179) or CCR (N=179): BSC only (N=105, 59%), LDAC (N=49, 27%), or Std CT (N=25, 14%). Median age was 69 yrs (38–88) and per treatment (TX): AZA (69 yrs); BSC only (70 yrs); LDAC (71 yrs); and Std CT (65 yrs). The AZA and CCR groups were comparable for baseline (BL) parameters. At BL, 95% of pts were higher risk: RAEB (58%), RAEB-T/WHO AML (34%), CMML (3%), and other (5%). By IPSS, 87% were higher risk: Int-2 (40%), High (47%), and 13% indeterminate/other. AZA was administered for a median of 9 cycles; LDAC for 4 cycles. Median followup for the OS analysis was 21.1 months (mo). AZA demonstrated statistically superior OS vs CCR (stratified log-rank p=0.0001). AZA showed a median Kaplan-Meier (KM) OS time of 24.4 mo vs 15 mo with CCR (Figure). The hazard ratio (HR, Cox Model) was 0.58 (95% CI: 0.43, 0.77) for a 74% OS improvement. At 2 yrs, there was a 2-fold OS advantage: AZA (51%) vs CCR (26%), 95% CI: 13, 36%, p&lt;0.0001. Differences in OS KM medians (HR; log-rank p) between AZA and BSC, LDAC, and Std CT, respectively, were 12.9 mo (0.55; p=0.0003), 9.1 mo (0.60; p=0.016), and 8.7 mo (0.69; p=0.19). Median OS per IPSS cytogenetic subgroup showed similar results (Table). The 1, 2, and 3-mo survival rates did not differ between AZA and BSC only (p&gt;0.20). AZA was well tolerated with safety data consistent with previous reports. Conclusion: These data confirm and extend previous CALGB findings. This AZA trial is the first MDS clinical study to demonstrate a significant OS advantage, thus altering the natural disease course. AZA should now be considered first-line therapy for higher-risk MDS pts. OS Analyses per IPSS Cytogenetic Group Group % (n/N) Pts AZA Median (Months) CCR Median (Months) HR (95%CI) Log-rank p Good 46 (166/358) Not reached 17.1 0.61 (0.39, 0.96) 0.030 Intermediate 21 (76/358) 26.3 17.0 0.43 (0.21, 0.88) 0.017 Poor 28 (100/358) 17.2 6.0 0.52 (0.32, 0.87) 0.011 Figure Figure
Novel anti-myeloma agents and angiogenesis (2008)

During the last decade several novel agents have been used in the management of patients with multiple myeloma. Immunomodulatory drugs and proteasome inhibitors exert their efficacy both directly by inducing apoptosis of myeloma cells and indirectly through the interruption of the interactions between myeloma and stromal cells in the bone marrow (BM) microenvironment. These interactions are crucial for myeloma cell growth and survival. The adherence of myeloma cells to BM stromal cells leads to the overproduction of several cytokines with angiogenic properties that enhance the survival and growth of myeloma cells through paracrine and autocrine loops. The correlation of these molecules with clinical features and survival of myeloma patients supports the importance of angiogenesis in the pathogenesis of the disease and reveals these cytokines as suitable targets for the development of novel anti-myeloma therapies. This review summarises all available preclinical and clinical data for the effect of novel agents that are used in myeloma therapy, such as thalidomide, lenalidomide, bortezomib and VEGF inhibitors, on angiogenesis, which is at least partially responsible for their remarkable anti-myeloma efficacy.
Characterization of foot-and-mouth disease virus gene products with antisera against bacterially synthesized fusion proteins (1986)

Defined segments of the cloned foot-and-mouth disease virus genome corresponding to all parts of the coding region were expressed in Escherichia coli as fusions to the N-terminal part of the MS2-polymerase gene under the control of the inducible lambda PL promoter. All constructs yielded large amounts of proteins, which were purified and used to raise sequence-specific antisera in rabbits. These antisera were used to identify the corresponding viral gene products in 35S-labeled extracts from foot-and-mouth disease virus gene products in the nucleotide sequence, to identify precursor-product relationships, and to detect several foot-and-mouth disease virus gene products not previously identified in vivo or in vitro.
Stereolithography and Other Rp&m Technologies: From Rapid Prototyping to Rapid Tooling (1995)

Whether you're a designer, a mechanical or manufacturing engineer, member of a concurrent engineering team, a manager or a manufacturing educator, this book will quickly become your primary source for rapid prototyping information. RP material selection is addressed so manufacturers understand which process/material will produce the best model for their use.
Increased sitosterol absorption, decreased removal, and expanded body pools compensate for reduced cholesterol synthesis in sitosterolemia with xanthomatosis. (1989)

We measured the turnover and absorption of sitosterol and cholesterol, along with plasma sterol and lipoprotein concentrations, in one control and two subjects with sitosterolemia with xanthomatosis. All individuals consumed the same diet which contained approximately 500 mg/day of cholesterol and 250 mg/day of sitosterol. Sterol absorption was measured by the plasma dual-isotope ratio method and turnover by plasma isotope-kinetic analysis. In two sitosterolemic subjects, 28% and 63% of the sitosterol and 69% and 49% of the cholesterol were absorbed, respectively, compared to 4% of the sitosterol and 44% of the cholesterol in the control. As expected, plasma sitosterol specific activities decayed much more rapidly than cholesterol in the control subject. In contrast, plasma sitosterol and cholesterol specific activity-time curves were similar and decayed more slowly in the sitosterolemic subjects. In the control subject, the total sitotterol pool was 290 mg and was linearly related to low absorption (18 mg/day); whereas the total sitosterol pool was 17 times (4800 mg) and 13 times (3500 mg) larger, respectively, in the sitosterolemic subjects and was expanded out of proportion to increased absorption because of decreased removal. Daily cholesterol turnover and synthesis were markedly reduced in the sitosterolemic subjects. In four sitosterolemic subjects, plasma concentrations of total sterols, low density lipoproteins, and apolipoprotein B were increased, while those of high density lipoproteins and apolipoprotein A-I were low to normal. The low density lipoproteins were very similar to those of normal control subjects in density distribution, peak flotation rate, sterol-to-protein (apolipoprotein B) ratio, particle size, and morphology. These results demonstrate in patients with sitosterolemia with xanthomatosis that: 1) the absorption of sitosterol and cholesterol is enhanced; 2) tissue recognition between cholesterol and sitosterol is lost; 3) total exchangeable sitosterol pools are expanded out of proportion to absorption because of decreased excretion; 4) plasma sterol and lipoprotein concentrations favor tissue deposition; and 5) cholesterol synthesis is diminished. We postulate that the changes in sitosterol metabolism (increased absorption, loss of tissue sterol structural recognition, expanded pools, and hepatic retention) are a response to reduced cholesterol synthesis in these subject.
Implementing spike-timing-dependent plasticity on SpiNNaker neuromorphic hardware (2010)

This paper presents an efficient approach for implementing spike-timing-dependent plasticity (STDP) on the SpiNNaker neuromorphic hardware. The event-address mapping and the distributed synaptic weight storage schemes used in parallel neuromorphic hardware such as SpiNNaker make the conventional pre-post-sensitive scheme of STDP implementation inefficient, since STDP is triggered when either a pre- or post-synaptic neuron fires. An alternative pre-sensitive scheme approach is presented to solve this problem, where STDP is triggered only when a pre-synaptic neuron fires. An associated deferred event-driven model is developed to enable the pre-sensitive scheme by deferring the STDP process until there are sufficient history spike timing records. The paper gives detailed description of the implementation as well as performance estimation of STDP on multi-chip SpiNNaker machine, along with the discussion on some issues related to efficient STDP implementation on a parallel neuromorphic hardware.
Human monoamine oxidase A and B genes exhibit identical exon-intron organization. (1991)

Monoamine oxidases A and B [MAOA and MAOB; amine:oxygen oxidoreductase (deaminating) (flavin-containing), EC 1.4.3.4] play important roles in the metabolism of neuroactive, vasoactive amines and the Parkinsonism-producing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Human MAOA and MAOB genes isolated from X chromosome-specific libraries span at least 60 kilobases, consist of 15 exons, and exhibit identical exon-intron organization. Exon 12 codes for the covalent FAD-binding-site and is the most conserved exon; the MAOA and MAOB exon 12 products share 93.9% peptide identity. These results suggest that MAOA and MAOB are derived from duplication of a common ancestral gene and provide insight on the structural/functional relationship of the enzyme products.
Differential Regulation of Human Lung Epithelial and Endothelial Barrier Function by Thrombin (2004)

Lung epithelial and endothelial barrier dysfunction is critical to the physiologic derangement observed in acute lung injury, but remains poorly understood. We utilized human alveolar epithelial (A549) and endothelial cells (EC) to study cytoskeletal remodeling, myosin light chain (MLC) phosphorylation and barrier regulation evoked by the edemagenic agent, thrombin. Thrombin-challenged human EC monolayers demonstrated increased MLC phosphorylation, actin stress fiber formation and loss of barrier integrity reflected by decreased transmonolayer electrical resistance (TER). In contrast, thrombin produced prominent circumferential localization of actin fibers, increased MLC phosphorylation and increased TER across epithelial monolayers, consistent with barrier protection. Reductions in MLC phosphorylation induced by cell pretreatment with pharmacological inhibitors of MLC kinase (ML-7) and Rho kinase (Y-27632) significantly attenuated thrombin-mediated TER changes and MLC phosphorylation in both lung cell types. Thrombin-produced, time-dependent activation of Rho GTPase in both epithelial and EC, whereas Rac GTPase activation was observed only in A549 cells. Molecular inhibition of Rac activity by adenoviral transfer of dominant-negative Rac mutant abolished thrombin-induced TER increases in alveolar epithelial cells. Finally, A549 cells, but not endothelium, demonstrated increased levels of tight junction proteins (ZO-1 and occludin) after thrombin at the cell-cell interface areas linked to thrombin-elicited barrier protection. These results demonstrate differential pulmonary endothelial and alveolar epithelial barrier regulation via unique actomyosin remodeling and cytoskeletal interactions with tight junction complexes, which confer selective barrier responses to edemagenic stimuli.
Chromosomal DNA from a variety of bacterial species is present in synovial tissue from patients with various forms of arthritis (2001)

This analysis provides the first systematic attempt to relate bacterial nucleic acids in the synovium to clinical characteristics, joint findings, and outcomes. Many patients with arthritis have bacterial DNA in the joint, and, in some cases, DNA from more than a single species is present. However, except for 1 case of a control patient with staphylococcal septic arthritis, it is not clear from the present study whether the synovial presence of such organisms is related to disease pathogenesis or evolution in any or all cases.
Liposomal Formulations of Synthetic MUC1 Peptides:  Effects of Encapsulation versus Surface Display of Peptides on Immune Responses (1998)

Synthetic human MUC1 peptides are important candidates for therapeutic cancer vaccines. To explore whether a human MUC1 peptide BP25 (STAPPAHGVTSAPDTRPAPGSTAPP) can be rendered immunogenic by incorporation in liposomes, the effects of physical association of the peptide with liposomes on immune responses were investigated. Lipid conjugated and nonconjugated MUC1 peptides were incorporated in liposomes with a composition of distearoylphosphatidylcholine/cholesterol/dimyristoylphosphatidylglyc erol (3:1:0.25, molar ratio) containing monophosphoryl lipid A (1% w/w of the total lipids). Liposomes were characterized for peptide retention by HPLC and for surface peptide display of MUC1 epitopes by flow cytometry. C57BL/6 mice were immunized with lipopeptide alone, peptide mixed with peptide-free liposomes, and peptide associated with liposomes in entrapped or surface-exposed forms. T cell proliferative responses, cytokine patterns, and antibody isotypes were studied. Results showed that immune responses were profoundly influenced by the liposome formulations. Physically associated, either encapsulated or surface-exposed, peptide liposomes elicited strong antigen-specific T cell responses, but not lipopeptide alone or peptide mixed with peptide-free liposomes. Analysis of the cytokines secreted by the proliferating T cells showed a high level of IFN-gamma and undetectable levels of IL-4, indicating a T helper type 1 response. Thus, physical association of the peptide with liposomes was required for T cell proliferative responses, but the mode of association was not critical. On the other hand, the nature of the association significantly affected humoral immune responses. Only the surface-exposed peptide liposomes induced MUC1-specific antibodies. A domination of anti-MUC1 IgG2b over IgG1 (94 versus 6%) was observed. Our results support the hypothesis that different immune pathways are stimulated by different liposome formulations. This study demonstrated that a liposome delivery system could be tailored to induce either a preferential cellular or humoral immune response.
Partial Least Squares (PLS) Regression. (2003)

Pls regression is a recent technique that generalizes and combines features from principal component analysis and multiple regression. It is particularly useful when we need to predict a set of dependent variables from a (very) large set of independent variables (i.e., predictors). It originated in the social sciences
Probing the mechanism of horseradish peroxidase by site-directed mutagenesis (1992)

Conference Article| May 01 1992 Probing the mechanism of horseradish peroxidase by site-directed mutagenesis A. T. Smith; A. T. Smith *Biochemistry Laboratory, University of Sussex, Brighton BN1 9QR, U.K. Search for other works by this author on: This Site PubMed Google Scholar S. A. Sanders; S. A. Sanders *Biochemistry Laboratory, University of Sussex, Brighton BN1 9QR, U.K. Search for other works by this author on: This Site PubMed Google Scholar H. Greschik; H. Greschik *Biochemistry Laboratory, University of Sussex, Brighton BN1 9QR, U.K. Search for other works by this author on: This Site PubMed Google Scholar R. N. F. Thorneley; R. N. F. Thorneley †AFRC-IPSR Nitrogen Fixation Laboratory, University of Sussex, Brighton BN1 9QR, U.K. Search for other works by this author on: This Site PubMed Google Scholar J. F. Burke; J. F. Burke *Biochemistry Laboratory, University of Sussex, Brighton BN1 9QR, U.K. Search for other works by this author on: This Site PubMed Google Scholar R. C. Bray R. C. Bray *Biochemistry Laboratory, University of Sussex, Brighton BN1 9QR, U.K. Search for other works by this author on: This Site PubMed Google Scholar Biochem Soc Trans (1992) 20 (2): 340–345. https://doi.org/10.1042/bst0200340 Article history Received: December 18 1991 Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Cite Icon Cite Get Permissions Citation A. T. Smith, S. A. Sanders, H. Greschik, R. N. F. Thorneley, J. F. Burke, R. C. Bray; Probing the mechanism of horseradish peroxidase by site-directed mutagenesis. Biochem Soc Trans 1 May 1992; 20 (2): 340–345. doi: https://doi.org/10.1042/bst0200340 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsBiochemical Society Transactions Search Advanced Search Keywords: CCP, cytochrome c peroxidase, HRP, horseradish peroxidase, HRP-C, HRP isoenzyme C, HRP-C*, non-glycosylated recombinant HRP-C*, ABTS, 2,2′-azido-bis(3-ethylbenzthiazoline-6-sulphonate), PABA, p-aminobenzoic acid, BHA, benzhydroxamic acid, CAPS, 3-[eyclohexylamino]-1-propanesulphonic acid, CHHS, 2-[N-cyclohexylamino]ethanesulphonic acid This content is only available as a PDF. © 1992 Biochemical Society1992 Article PDF first page preview Close Modal You do not currently have access to this content.
Reducing false positive responses in lung nodule detector system by asymmetric adaboost (2008)

We are developing a complex computer aided diagnosis (CAD) system to detect small pulmonary nodules from helical CT scans. Here we present a classifier to reduce the number of false positive responses of the primary detector. Our approach is based on an asymmetric Adaboost which enables us to give different weights to missed nodules (false negatives, FNs) and incorrectly detected structures (false positives, FPs). This is useful because there are noticeably more negative examples in the nodule candidate set than real nodules-true positives (TPs). The whole system is meant as a second opinion for a human radiologist to speed up reading the examination. That is why we should detect as many true nodules as possible, while a certain number of FPs is acceptable. The system was tested on 147 cases (36559 slices) containing 357 nodules marked by an expert radiologist. The new classifier significantly reduced the number of false positives, while only a few nodules were incorrectly omitted.